BACKGROUND/OBJECTIVES:Infants and Toddlers Dermatology Quality of Life (InToDermQoL) questionnaire makes it possible to assess QoL in the youngest children with acute (AU) and chronic urticaria (CU). The aim of this study was to assess the impact of AU and CU on QoL and family QoL of children from birth to 4 years. METHODS:The data were collected in Spain, Greece, and Ukraine. Parents of children with AU and CU were asked to complete the InToDermQoL, Family Dermatology Life Quality Index (FDLQI), and Family Reported Outcome Measure (FROM-16). Disease severity was measured by the global severity and Urticaria Activity Score 7 (UAS7). RESULTS:Among 108 children with AU 44.44% had severe and 28.70% had moderate effect on their QoL. Eight of eleven children with CU had a severe effect on their lives. The InToDermQoL correlated with FDLQI (r = 0.78-0.88), global disease severity (r = 0.68-0.76), UAS7 (r = 0.77) and FROM-16 (r = 0.82). FDLQI was well correlated with FROM-16 (r = 0.83) and global disease severity (r = 0.63). UAS7 was well correlated with the FDLQI (r = 0.77) and FROM-16 (r = 0.73). In children with CU, there was more severe impact on itching or scratching, bleeding, sleep, bathing, physical activity, and problems with treatment. Their families noted more impact on personal relationships, leisure activities, looking after relative, extra housework, affected job, and expenditure. CONCLUSIONS:AU and CU have a significant impact on children's QoL and family QoL. InToDermQoL, FDLQI, and FROM-16 well reflected QoL and family QoL impairment in young children with urticaria. More active educational work with their parents is needed.

T-cell-redirecting immunotherapies, including bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies, have rapidly become major treatment options of relapsed or refractory multiple myeloma but are associated with a distinctive spectrum of cutaneous toxicities. Dermatologic manifestations are particularly prominent with GPRC5D-targeting agents, reflecting on-target, off-tumor activity against hard-keratinizing tissues, whereas BCMA-targeted bispecific antibodies and anti-BCMA CAR T-cell therapies are associated with milder and less phenotypically distinct cutaneous adverse events. Despite their clinical relevance, these toxicities remain inconsistently reported, and standardized definitions and management strategies are lacking. This European Academy of Dermatology and Venereology (EADV) Task Force "Dermatology for Cancer Patients" position paper, developed in collaboration with hematology units experienced in multiple myeloma care, reviews the mechanistic basis, clinical spectrum, and grading of cutaneous toxicities associated with T-cell-redirecting therapies. We propose a phenotype-driven, stepwise management framework organized around 4 principal patterns - barrier dysfunction and hyperkeratotic disease, inflammatory cutaneous eruptions, nail toxicity, and injection-site reactions- incorporating preventive strategies, baseline dermatologic assessment, and grade-adapted treatment algorithms.

Background and Objectives: Dermatology relies on a complex terminology encompassing lesion types, distribution patterns, colors, and specialized sites such as hair and nails, while dermoscopy adds an additional descriptive framework, making interpretation subjective and challenging. Our study aims to evaluate the ability of a chatbot (Gemini 2) to generate dermatology descriptions across multiple languages and image types, and to assess the influence of prompt language on readability, completeness, and terminology consistency. Our research is based on the concept that non-English prompts are not mere translations of the English prompts but are independently generated texts that reflect medical and dermatological knowledge learned from non-English material used in the chatbot’s training. Materials and Methods: Five macroscopic and five dermoscopic images of common skin lesions were used. Images were uploaded to Gemini 2 with language-specific prompts requesting short paragraphs describing visible features and possible diagnoses. A total of 2400 outputs were analyzed for readability using LIX score and CLEAR (comprehensiveness, accuracy, evidence-based content, appropriateness, and relevance) assessment, while terminology consistency was evaluated via SNOMED CT mapping across English, French, German, and Greek outputs. Results: English and French descriptions were found to be harder to read and more sophisticated, while SNOMED CT mapping revealed the largest terminology mismatch in German and the smallest in French. English texts and macroscopic images achieved the highest accuracy, completeness, and readability based on CLEAR assessment, whereas dermoscopic images and non-English texts presented greater challenges. Conclusions: Overall, partial terminology inconsistencies and cross-lingual variations highlighted that the language of the prompt plays a critical role in shaping AI-generated dermatology descriptions.

Hidradenitis suppurativa (HS) has a profound negative impact on patients' Quality of Life (QoL). The European Academy of Dermatology and Venereology (EADV) Task Force (TF) on QoL and Patient Oriented Outcomes and TF on Acne, Rosacea and Hidradenitis Suppurativa (ARHS), together with external experts, decided to provide an updated position statement on QoL measurement in HS. In our previous position statement on HS, we stated that a Dermatology Life Quality Index (DLQI) score of 0-1, corresponding to no effect on patient's life according to the DLQI banding descriptions, may be considered as a difficult to reach but important treatment goal: achievement of this goal has since been used as an efficacy criterion in several clinical trials. For many HS treatment methods, there is still a lack of well-organized randomized clinical trials with sufficient participant numbers in which QoL instruments have been used as outcome measures. The DLQI is the most widely used QoL instrument in HS. Clinical recommendations and treatment efficacy are based on its score grading system and minimal clinically important difference (MCID). The HS-specific QoL instruments HSIA, HSQoL-24, HiSQOL, and QoL-HS have a satisfactory number of items for routine clinical use and short recall periods. HiSQOL and HSQoL-24 have score grading systems and the MCID for HiSQOL has been established. The TF on QoL and Patient Oriented Outcomes and TF on ARHS recommend that QoL be assessed in HS: dermatology-specific and HS-specific instruments may be used alongside each other.

INTRODUCTION:Simultaneous international validation of the QOLRELEVANCE-ACNE questionnaire confirmed its convergent validity, internal consistency and test-retest reliability. A grading system of the QOLRELEVANCE-ACNE questionnaire scores was accepted. The objective of the present study was to confirm the responsiveness and establish the Minimally Clinically Important Difference (MCID) for the QOLRELEVANCE-ACNE questionnaire. METHODS:Patients with acne were asked to fill in the QOLRELEVANCE-ACNE and Dermatology Life Quality Index (DLQI) questionnaires. Global acne severity was assessed independently by both dermatologists and patients. Cohen's d, anchor-based approach and the receiver operating characteristic (ROC) curves method were used for confirmation of responsiveness and determination of MCIDs of the QOLRELEVANCE-ACNE questionnaire. RESULTS:The results of 576 acne patients across eight countries (Bulgaria, Croatia, Germany, Greece, Malta, Romania, Spain and Turkey) were analysed. Cohen d was 0.8. Estimated MID was 2.64. The nearest integer above calculated MID is 3. Based on the hypothesis that total scores below MID correspond to no effect on patient's HRQoL, total QOLRELEVANCE-ACNE scores from 0 to 2 correspond to no effect on patient's HRQoL. Correlations coefficient between changes of the QOLRELEVANCE-ACNE scores and changes of the acne severity assessed by the dermatologist and by the patient and changes of the DLQI scores were 0.61, 0.59 and 0.70, respectively. AUCs were excellent (above 0.8). Calculated MCIDs were 3. CONCLUSION:All used methods confirmed excellent responsiveness of the QOLRELEVANCE-ACNE questionnaire. The MCID of 3 for QOLRELEVANCE-ACNE was established. Total QOLRELEVANCE-ACNE scores of 0, 1 and 2 correspond to no effect on patients' life.

BACKGROUND:With the widespread use of immune checkpoint inhibitors (ICI), rare cutaneous immune-related adverse events (cirAEs), including ICI-induced eosinophilic fasciitis (ICI-EF), are increasingly encountered. However, data on its clinical presentation and optimal therapeutic approaches remain sparse. OBJECTIVES:This study aimed to further characterize the clinical features and outcomes of ICI-EF. METHODS:This retrospective observational study analysed clinical features, treatment strategies and outcomes of ICI-EF cases from EADV Task Force-affiliated dermatology departments, complemented by cases from the current available literature and two international pharmacovigilance databases. Patient demographics, clinical characteristics, diagnostics, treatment and follow-up data were extracted from the medical records and databases. RESULTS:We present 121 ICI-EF cases from the EADV Task Force (n = 15), FPVD (n = 21), VigiBase® (n = 45) and the literature (n = 40). The most prevalent underlying malignancy in all groups was melanoma (50%), with PD-1 inhibitor monotherapy (81%) being the predominant offending drug class. The median time to ICI-EF onset was 10 months (IQR 6.8-16.3; range < 1-36). Detailed clinical information was available for 76 of the 121 cases (63%), revealing a highly variable clinical presentation. Treatment primarily involved ICI discontinuation (83%) and systemic corticosteroids (80%), followed by methotrexate (41%), intravenous immunoglobulins (12%) and mycophenolate mofetil (13%), resulting in the partial or complete resolution of ICI-EF symptoms (66%). CONCLUSIONS:ICI-EF is a rare heterogeneous cirAE with varying clinical features and significant morbidity. Early recognition and timely treatment are key to ensuring ICI continuation and preserve oncologic outcomes.

This case series describes lipodystrophy, a rare adverse event associated with immune checkpoint inhibitor therapy.

The emergence of systemic therapies and photoprotection against non-melanoma skin cancer (NMSC) raises questions on the broader systematic impact of the disease. Personalized medicine involves a holistic patient approach, through which the evaluation of systemic biomarkers can reveal the interconnected aspects of patient health and tailored therapies. Cumulative UV exposure disrupts redox equilibrium and triggers inflammation and cutaneous immunosuppression, processes that contribute independently or via their interplay to cutaneous carcinogenesis. This systemic impact can be further reinforced by biomolecules derived from the NMSC microenvironment, fueling a continuous cycle of oxidative stress and inflammation in the organism. Regarding investigation of the systemic burden of NMSC, we conducted a narrative review focusing on parameters related to redox status, inflammation, and immune suppression observed in the blood components (serum, plasma, and erythrocytes) of NMSC patients. Our findings revealed an association of NMSC patients with perturbations of redox homeostasis, as evidenced by the decreased antioxidant activity, lower levels of non-enzymatic antioxidants, and increased byproducts of lipid, protein, and DNA oxidative damage. Additionally, NMSC patients presented augmented levels of pro-inflammatory interleukins, reduced anti-tumor biomolecule levels, and enhanced immune response markers, as well as elevated vitamin D levels. These systemic changes may lead to the association of NMSC with a higher risk of secondary malignancies in other organs. Overall, the findings of the present study suggest that NMSC affects systemic health beyond the skin, underscoring the need for a comprehensive and individualized approach to the management and monitoring of the patient.

Cancer immunotherapy, particularly immune checkpoint inhibitors (ICI), has revolutionized oncology treatment by leveraging the immune system to recognize and eliminate cancer cells. However, despite its efficacy, immunotherapy may induce immune-related adverse events (irAEs), including dermatological events, that can range from mild rashes to severe life-threatening conditions such as toxic epidermal necrolysis. This paper aims to explore and analyse the preventive measures for cutaneous irAEs (cirAEs). By identifying risk factors, recognizing early signs and implementing preventive strategies, healthcare professionals can significantly mitigate the severity of irAEs, thereby improving patient outcomes and quality of life.